Merck Research Laboratories

Latest articles

22d
Business Wire
Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)cancer,” said Roger Dansey, M.D., senior vice president and therapeutic area he
Business Wire / Posted 22 days ago
cancer,” said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “We look forward to sharing the comprehensive data analysis from KEYNOTE-040 with the scientific... Read more

In this news